Navigation Links
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
Date:5/5/2009

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that a New Drug Application (NDA) for exenatide once weekly has been submitted to the U.S. Food and Drug Administration (FDA). Exenatide once weekly is an investigational sustained release medication for type 2 diabetes that is injected subcutaneously and administered only once a week. Exenatide is the active ingredient in BYETTA(R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic control with common oral therapies.

"The exenatide once weekly submission is an important milestone in the overall exenatide development program. The clinical data supporting this submission highlight the potential of exenatide once weekly to significantly advance the treatment of type 2 diabetes," said Daniel M. Bradbury, president and chief executive officer of Amylin. "We remain committed to developing and commercializing a range of treatment options that address the important unmet needs of people living with diabetes."

Clinical components of the NDA include the DURATION-1 study and the meta-analysis of primary cardiovascular events across the BYETTA clinical database. DURATION-1 was designed to test the superiority of exenatide once weekly, as compared to BYETTA, which is administered twice daily. In this study, exenatide once weekly treatment resulted in statistically significant reductions in A1C of 1.9 percentage points from baseli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
6. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
9. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Program Connects Customers with Partn...cted with DNA Genotek Products , ...NA Genotek , a leading provider of products for bi...aration, today announced its new global partner pr... for DNA Genotek,s partner community and is design...
(Date:11/23/2009)...Ill. You can think of it as origami very high-te...linois have developed a technique for fabricating ...ctures from thin films by coupling photolithograph...nteractions. , The films, only a few microns thic...le with thicker pieces of the same material. , "T...
(Date:11/23/2009)...SSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioScienc...developmentcompanythatidentifiesandadvancesadivers...usstagesofdevelopment,todayreportedthatCytopia(ASX...tingCYT387,apotent,orally-administeredJAK1/JAK2inh...ster,Minnesota.AproposaltomergeCytopiaintoYMhasbee...
(Date:11/23/2009)...BY,BC,Nov.23/PRNewswire/-InimexPharmaceuticals,Inc...h.DasitsPresidentandCEO. ,, Abramsbringsmoretha...nimex.Heisaco-inventorofthenuclearmedicineimaginga...tthey,plcwherehewasManager,BiomedicalResearchWorld...ngley,BCandwasPresidentandCEOfrom1996to2006.AnorME...
Breaking Biology Technology:DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Inimex Announces Appointment of New CEO 2
...f Operations Outside the US In ...Nov. 6 Northwest,Biotherapeutics, Inc. (OTC Bulle...ced that it has obtained US$1.65 million in fundin... (the "Notes") with SDS Capital Group SPC,Ltd ("SD... Investors"). A,significant portion of the proceed...
...ing Process Documentation for Customer ...., Nov. 5 BioLife Solutions Inc.,(OTC Bulletin Bo...oprietary,hypothermic storage and cryopreservation...ay announced that it has submitted a Master File t...FDA) for the Company,s,HypoThermosol preservation ...
...Technologies, Inc.,a provider of innovative microd...e research, today announced that it has shipped it...application to The Genome Center (GC) at,the Washi...a world leader,in genomics research., Under RainD...l provide,its new RDT 1000 and expert training to ...
Other Biology Technology:Northwest Secures US$1.65 Million Debt Financing 2Northwest Secures US$1.65 Million Debt Financing 3Northwest Secures US$1.65 Million Debt Financing 4BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 2BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 3RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to The Genome Center at Washington University School of Medicine in St. Louis 2
(Date:11/23/2009)...evidence that the "synergistic" effect of early-li...ion and indoor endotoxin causes more harm to devel... , Environmental health scientists at the Unive...shown that children exposed to both high levels of...ring early life are six times more likely to exper...
(Date:11/23/2009)...ion Society says that western lowland gorillas liv...of the "mother lode" of more than 125,000 gorillas...eatened by growing humans activity in the region. ...orests adjacent to the southwest border of Lac Tl ...hat high densities of the great apes still exist i...
(Date:11/23/2009)...vailable for the H1N1 virus has been sent to vacci...cination marks the first time vaccine has been sen..., Iowa State University,s Hank Harris, professor...mer and has been shipping preventive doses to swin...al weeks., The latest vaccines were shipped to a...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2MitraClip 28R 29 Therapy Introduced in Austria 4958 1MitraClip 28R 29 Therapy Introduced in Austria 4958 2MitraClip 28R 29 Therapy Introduced in Austria 4958 3Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 56624 1Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 56624 2Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 56624 3Mayo Clinic Center for Innovation Collaborative Symposium on Innovations in Health Care Experience 56624 4Peter G Peterson Foundation Releases The Lewin Group Study Showing Current House Health Care Reform Proposal Would Lead to Expanded Coverage and High 56622 1Peter G Peterson Foundation Releases The Lewin Group Study Showing Current House Health Care Reform Proposal Would Lead to Expanded Coverage and High 56622 2Peter G Peterson Foundation Releases The Lewin Group Study Showing Current House Health Care Reform Proposal Would Lead to Expanded Coverage and High 56622 3Peter G Peterson Foundation Releases The Lewin Group Study Showing Current House Health Care Reform Proposal Would Lead to Expanded Coverage and High 56622 4
...ia, PA September 4, 2008) The tumor suppressor ge...gnostic biomarker in cases of soft tissue sarcoma ... of researchers, including scientists at the Sbarr...cine at the College of Science and Technology at T...nt of Human Pathology and Oncology, University of ...
...l. (Sept. 3, 2008) Scientists at the U.S. Departm...have won an $800,000 EUREKA award from the Nationa...precise molecular ruler for measuring distances wi...Multi-wavelength Anomalous Diffraction using Mediu...dramatically reduce the time necessary to reveal t...
... Conn. Yale molecular and evolutionary biologists ...sts produced the full genome sequence of Trichopl...organisms, providing a new insight into the evolut...d in the online edition of the journal Nature sh... nuclear genomes found in a multi-cellular creatur...
Other Biology News:International team reveals first prognosticator of survival in aggressive cancer 2NIH awards Argonne $800,000 to develop tool to measure distances within proteins 2Trichoplax genome sequenced -- 'rosetta stone' for understanding evolution 2
Rat Anti-Mouse OSMR Monoclonal Antibody, Unconjugated, Clone 30-1 from MBL International
Mouse Anti-ROCK-1 (cleaved) Monoclonal Antibody, Unconjugated from BioVision
Mouse Anti-Chloramphenicol Acetyltransferase Monoclonal Antibody, Unconjugated, Clone CAT-1 from Abcam
mCD-1 Multi-Probe Template Set from BD Biosciences Pharmingen
Biology Products: